Milestone Pharmaceuticals Inc.

NasdaqGS MIST

Milestone Pharmaceuticals Inc. Return on Assets (ROA) for the year ending December 31, 2023

Milestone Pharmaceuticals Inc. Return on Assets (ROA) is NA for the year ending December 31, 2023. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Milestone Pharmaceuticals Inc. Return on Assets (ROA) for the year ending December 31, 2022 was -76.71%.
Milestone Pharmaceuticals Inc. Return on Assets (ROA) for the year ending December 31, 2020 was -33.32%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGS: MIST

Milestone Pharmaceuticals Inc.

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard
Employees	47
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends

Past 5 years